INTRAVITREAL BEVACIZUMAB for INFLAMMATORY CHOROIDAL NEOVASCULARIZATION Results from the Pan-American Collaborative Retina Study Group at 24 Months

Página do item simplificado
dc.contributor.authorArevalo, J. Fernando
dc.contributor.authorAdan, Alfredo
dc.contributor.authorBerrocal, Maria H.
dc.contributor.authorEspinoza, Juan V.
dc.contributor.authorMaia, Mauricio [UNIFESP]
dc.contributor.authorWu, Lihteh
dc.contributor.authorRoca, Jose A.
dc.contributor.authorQuiroz-Mercado, Hugo
dc.contributor.authorRuiz-Moreno, Jose M.
dc.contributor.authorSerrano, Martin A.
dc.contributor.authorPan-Amer Collaborat Retina Study
dc.contributor.institutionEdif Ctr Caracas PH 1
dc.contributor.institutionHosp Clin Barcelona
dc.contributor.institutionUniv Puerto Rico
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionClin Ricardo Palma
dc.contributor.institutionHosp Dr Luis Sanchez Bulnes
dc.contributor.institutionInst Oftalmol Alicante
dc.contributor.institutionMiguel Hernandez Univ
dc.date.accessioned2016-01-24T14:06:09Z
dc.date.available2016-01-24T14:06:09Z
dc.date.issued2011-02-01
dc.description.abstractBackground: To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in the treatment of inflammatory choroidal neovascularization at 24 months.Methods: We reviewed the clinical records of 22 consecutive patients (23 eyes) with choroidal neovascularization secondary to chorioretinal inflammatory disease in this interventional retrospective multicenter case series. Sixteen eyes (63.6%) received a dose of 1.25 mg of intravitreal bevacizumab, and 7 eyes (36.4%) received a dose of 2.5 mg of intravitreal bevacizumab.Results: At baseline, the mean best-corrected visual acuity was 0.68 logarithm of minimum angle of resolution (Early Treatment Diabetic Retinopathy Study chart = 20/100). After intravitreal bevacizumab, best-corrected visual acuity improved significantly to 0.41 logarithm of minimum angle of resolution (20/51), 0.42 logarithm of minimum angle of resolution (20/53), and 0.40 logarithm of minimum angle of resolution (20/50) at 6, 12, and 24 months, respectively (P < 0.05). Fourteen eyes (60.8%) received 1 injection. Central macular thickness by optical coherence tomography decreased from 375.3 mu m (range: 240-634 mu m) at baseline to 241.6 mu m (range: 189-306 mu m) at 24 months of follow-up (P < 0.0001).Conclusion: Intravitreal bevacizumab at doses of 1.25 mg and 2.5 mg seems to provide stability or improvement in best- corrected visual acuity, optical coherence tomography, and fluorescein angiogram in inflammatory choroidal neovascularization at 24 months. All patients were treated after the underlying uveitic condition was controlled.RETINA 31: 353-363, 2011en
dc.description.affiliationEdif Ctr Caracas PH 1, Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela
dc.description.affiliationHosp Clin Barcelona, Dept Ophthalmol, Barcelona, Spain
dc.description.affiliationUniv Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.affiliationInst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliationClin Ricardo Palma, Lima, Peru
dc.description.affiliationHosp Dr Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Mexico City, DF, Mexico
dc.description.affiliationInst Oftalmol Alicante, Unidad Vitreo Retinal, Alicante, Spain
dc.description.affiliationMiguel Hernandez Univ, Escuela Med, Alicante, Spain
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipArevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
dc.format.extent353-363
dc.identifierhttp://dx.doi.org/10.1097/IAE.0b013e3181ed8cec
dc.identifier.citationRetina-the Journal of Retinal and Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 31, n. 2, p. 353-363, 2011.
dc.identifier.doi10.1097/IAE.0b013e3181ed8cec
dc.identifier.issn0275-004X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33434
dc.identifier.wosWOS:000286586500021
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofRetina-the Journal of Retinal and Vitreous Diseases
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAvastinen
dc.subjectbevacizumaben
dc.subjectchoroidal neovascularizationen
dc.subjectCNVen
dc.subjectinflammatoryen
dc.subjectintravitreal injectionsen
dc.titleINTRAVITREAL BEVACIZUMAB for INFLAMMATORY CHOROIDAL NEOVASCULARIZATION Results from the Pan-American Collaborative Retina Study Group at 24 Monthsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral